QLIF-27. THE ADDED VALUE OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AS A PROGNOSTIC INDICATOR OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOMA PATIENTS: A META-ANALYSIS BASED ON INDIVIDUAL PATIENT DATA FROM RANDOMIZED CONTROLLED TRIALS
Year: 2017
Type: conference-abstract
Abstract: Health-related quality of life (HRQoL) is of major importance in patients with glioma, the most common malignant primary brain tumor in adults. Our study investigated the added prognostic value of HRQoL for overall survival (OS) and progression free survival (PFS) in a large heterogeneous sample of both low and high-grade glioma patients, besides the known prognostic factors. We included individual baseline data from previously published randomized controlled trials (RCTs) in glioma patients in which HRQoL was a (secondary) endpoint, assessed with the EORTC QOL-C30 and QLQ-BN20. Multivariable cox models were used, first with sociodemographic/clinical variables only, and next with HRQoL variables added, separately for OS and PFS. C-indices were calculated to investigate the added prognostic value of HRQoL. Baseline HRQoL and sociodemographic/clinical data from eleven RCTs were included, totaling 4399 patients. After controlling for the sociodemographic/clinical variables age, sex, tumor type and stage, performance status, allocated treatment and previous resection, results showed that better cognitive functioning and less constipation and drowsiness were independently associated with a longer OS, and only better cognitive functioning with prolonged PFS. C-indexes indicated a small improvement of the model for OS and PFS when adding HRQoL to the sociodemographic/clinical prognostic variables (+1,2% for both OS and PFS). Our findings demonstrate that several baseline HRQoL variables were of individual prognostic importance for OS and PFS, yet the added value of HRQoL in comparison to the sociodemographic/clinical prognostic variables was small. Rather than baseline HRQoL data, a change in HRQoL from baseline during treatment, reflecting the impact of treatment, may be of more prognostic value and remains to be investigated.
Source: Neuro-Oncology
Authors: Marijke Coomans, Linda Dirven, Neil Aaronson, Brigitta G Baumert, Martin van den Bent, Andrew Bottomley, Alba Brandes, Olivier Chinot, Corneel Coens, Thierry Gorlia, Ulrich Herrlinger, Florence Keime-Guibert, Annika Malmström, Francesca Martinelli, Roger Stupp, Andrea Talacchi, Wolfgang Wick, Jaap C Reijneveld, Martin J B Taphoorn
Institutions: Leiden University Medical Center, Stichting Haaglanden Medisch Centrum, The Netherlands Cancer Institute, Maastricht University Medical Centre, Paracelsus-Kliniken, Erasmus MC, Erasmus MC Cancer Institute, European Organisation for Research and Treatment of Cancer, Istituto delle Scienze Neurologiche di Bologna, Aix-Marseille Université, University of Bonn, University Hospital Bonn, Pitié-Salpêtrière Hospital, Linköping University, Northwestern University, University of Verona, University Hospital Heidelberg, Amsterdam UMC Location University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2767299125